Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.9631) per share and revenue of $2.2220 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.
Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.14. The firm had revenue of $20.00 million during the quarter, compared to the consensus estimate of $7.50 million. On average, analysts expect Rapport Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Rapport Therapeutics Stock Performance
RAPP stock opened at $40.79 on Tuesday. The stock has a fifty day moving average of $39.41 and a 200-day moving average of $34.12. Rapport Therapeutics has a fifty-two week low of $13.62 and a fifty-two week high of $44.28. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of -15.69 and a beta of 0.97.
Analysts Set New Price Targets
View Our Latest Research Report on RAPP
Insider Activity
In other news, CEO Abraham Ceesay sold 2,210 shares of the stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $42.11, for a total value of $93,063.10. Following the sale, the chief executive officer directly owned 537,607 shares of the company’s stock, valued at approximately $22,638,630.77. This represents a 0.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Rock Ventures V. L.P. Third sold 18,572 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $40.05, for a total transaction of $743,808.60. Following the completion of the transaction, the insider owned 6,280,525 shares of the company’s stock, valued at $251,535,026.25. This trade represents a 0.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 430,913 shares of company stock worth $17,308,315. Company insiders own 12.48% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. Meeder Asset Management Inc. purchased a new position in Rapport Therapeutics during the fourth quarter worth about $37,000. Russell Investments Group Ltd. bought a new stake in shares of Rapport Therapeutics during the 3rd quarter valued at about $43,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Rapport Therapeutics by 86.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company’s stock worth $99,000 after purchasing an additional 4,582 shares in the last quarter. Creative Planning purchased a new position in shares of Rapport Therapeutics during the second quarter worth about $121,000. Finally, Bank of America Corp DE increased its position in shares of Rapport Therapeutics by 62.5% in the second quarter. Bank of America Corp DE now owns 12,127 shares of the company’s stock worth $138,000 after purchasing an additional 4,666 shares during the last quarter.
Rapport Therapeutics Company Profile
Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.
Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.
Read More
- Five stocks we like better than Rapport Therapeutics
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
